ArticleNature communications2023
Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Changes in RPV Resistance-Related Mutations Among Antiretroviral Therapy-Naïve HIV-1-Positive Individuals - China, 2004-2023.China CDC weekly · 2026Article
- Temporal trends and clinical outcomes of antiretroviral therapy initiation and regimens in treatment-naive people with HIV: A real-world study at a tertiary specialist hospital in Beijing, China.Infectious diseases & immunity · 2026Article
- Article
- Evolution of death trends and influencing factors of people living with HIV from 2003 to 2025 in Huangshi, China.BMC public health · 2026Article
- Data-driven Modeling of Long-term CD4 Cell Recovery Trajectories Under Modern Antiretroviral Therapy in People Living With HIV.Open forum infectious diseases · 2026Article
- "The clan carries us": kinship, honor, and the collective enactment of family resilience among Yi households living with HIV in rural Southwest China.BMC public health · 2026Article
- Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China.The Lancet regional health. Western Pacific · 2026Article
- Differences between different antiretroviral therapy regimens switching patterns among people living with HIV.BMC public health · 2026Article
- HIV-1 drug resistance and molecular transmission network analysis of newly diagnosed people living with HIV in Beijing, China: a retrospective study from 2015 to 2023.Virology journal · 2025Article
- The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China.PLOS global public health · 2025Article
- Human immunodeficiency virus/acquired immune deficiency syndrome antiretroviral therapy initiated on the same day in treatment-naïve people with human immunodeficiency virus: A comparative study of efficacy and regimen.Chinese medical journal · 2024Article
- Prognostic prediction models for treatment experienced people living with HIV: a protocol for systematic review and meta-analysis.BMJ open · 2024Article
- Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study.Immunity, inflammation and disease · 2024Article
- Longitudinal trajectories of weight changes among people living with HIV on antiretroviral therapy: A group-based study.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the proven virological advantages, there remains some controversy regarding whether first-line integrase strand transfer inhibitors (INSTIs)-based antiretroviral therapy (ART) contributes to reducing mortality of people living with HIV (PLHIV) in clinical practice. Here we report a retrospective study comparing all-cause mortality among PLHIV in China who were on different initial ART regimens (nevirapine, efavirenz, dolutegravir, lopinavir, and others [including darunavir, raltegravie, elvitegravir and rilpivirine]) between 2017 and 2019. A total of 41,018 individuals were included across China, representing 21.3% of newly reported HIV/AIDS cases collectively in the country during this period. Only the differences in all-cause mortality of PLHIV between the efavirenz group and the nevirapine group, the dolutegravir group and the nevirapine group, and the lopinavir group and the nevirapine group, were observed in China. After stratifying the cause of mortality, we found that the differences in mortality between initial ART regimens were mainly observed in AIDS-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.